Meta-analysis - Eltrombopag

This study has been completed.
Information provided by:
GlaxoSmithKline Identifier:
First received: November 4, 2010
Last updated: November 3, 2011
Last verified: November 2011
The purpose of the meta-analysis was to explore the efficacy of eltrombopag versus placebo (standard of care)

Condition Intervention
Drug: Eltrombopag
Drug: Placebo

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Systematic Review of the Clinical and Cost Effectiveness of Treatments for Idiopathic (Immune) Thrombocytopenic Purpura (ITP): Direct Meta Analysis

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • >=50 Gi/L platelet count to <400 Gi/L [ Time Frame: 43 days ] [ Designated as safety issue: No ]

Enrollment: 1
Study Start Date: August 2009
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Eltrombopag & standard of care Drug: Eltrombopag
Eltrombopag 50mg & standard of care
Standard of care Drug: Placebo
Placebo + standard of care

Detailed Description:
Meta-analysis of three studies: Bussell 2007 & Bussell 2009 & RAISE (TRA102537).

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Meta-analysis: A systematic review was conducted to obtain all relevant evidence relating to eltrombopag and relevant studies were selected

Inclusion Criteria:

  • Adults with ITP
  • Received a pre-specified treatment
  • Prospective clinical studies with at least 10 patients

Exclusion Criteria:

  • Subjects with ITP due to other causes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01235988

Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure Identifier: NCT01235988     History of Changes
Other Study ID Numbers: 114013
Study First Received: November 4, 2010
Last Updated: November 3, 2011
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Blood Platelet Disorders
Hematologic Diseases processed this record on November 25, 2015